CUTISS Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $27.8M

  • Investors
  • 14

CUTISS General Information

Description

Developer of customized bio-engineered skin grafts designed to treat large skin defects. The company's customized skin grafts use patient's cells in combination with a hydrogel to create dermo-epidermal skin and considerably reduce the need for autografting and further corrective interventions, allowing for considerable savings, enabling patients to get treated from affected skin or damaged skin and achieve the quality of life.

Contact Information

Website
www.cutiss.swiss
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • CUTISS Haus, Grabenstrasse 11
  • 8952 Schlieren
  • Switzerland
+41 044 000 00 00
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Other Healthcare Technology Systems
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • CUTISS Haus, Grabenstrasse 11
  • 8952 Schlieren
  • Switzerland
+41 044 000 00 00

CUTISS Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CUTISS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC (Series C) 21-May-2024 $27.8M 000.00 00000 Completed Clinical Trials - Phase 3
13. Grant 02-May-2023 00.000 000.00 Completed Clinical Trials - Phase 3
12. Later Stage VC 10-Feb-2023 000.00 000.00 00000 Completed Generating Revenue
11. Later Stage VC 17-Jun-2022 00.000 000.00 00000 Completed Clinical Trials - Phase 3
10. Accelerator/Incubator 28-Feb-2022 00.000 000.00 Completed Clinical Trials - Phase 1
9. Grant 25-Jan-2022 00000 000.00 Completed Clinical Trials - Phase 2
8. Later Stage VC 16-Dec-2020 00.000 000.00 000.00 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series B) 29-Jun-2020 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
6. Early Stage VC (Series A) 27-Jun-2018 $10.9M $12M 000.00 Completed Clinical Trials - Phase 1
5. Grant 01-Jan-2018 $4.05M $1.04M Completed Clinical Trials - Phase 1
To view CUTISS’s complete valuation and funding history, request access »

CUTISS Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference 000,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.00
Series B 000,000 00.000000 000.00 000.00 00 000.00 00.000
Series B 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series A 390,600 $0.109953 $27.49 $27.49 1x $27.49 10.38%
Series A 53,496 $0.109953 $21.99 $21.99 1x $21.99 1.42%
To view CUTISS’s complete cap table history, request access »

CUTISS Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of customized bio-engineered skin grafts designed to treat large skin defects. The company's customized skin g
Biotechnology
Schlieren, Switzerland
50 As of 2023
000.00
00000 0000-00-00
00000000000 000.00

000000

ehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Except
0000000000000
Ann Arbor, MI
000 As of 0000
00000
00000000 00000

000000

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor i
000000000000000
Dublin, Ireland
0000 As of 0000
00.00
0000000000.
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CUTISS Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vericel Corporation Ann Arbor, MI 000 00000 00000000 00000
Mallinckrodt Formerly PE-Backed Dublin, Ireland 0000 00.00 0000000000.
You’re viewing 2 of 2 competitors. Get the full list »

CUTISS Patents

  • 28

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 28

    Pending

  • 000

    Expiring in next 12 mo

CUTISS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022296956-A1 Tissue culture vessel for preparation of compressed hydrogel skin grafts and related methods and systems Pending 20-Jun-2021 000000000
CA-3223185-A1 Tissue culture vessel for preparation of compressed hydrogel skin grafts and related methods and systems Pending 20-Jun-2021 000000000
US-20240263116-A1 Tissue culture vessel for preparation of compressed hydrogel skin grafts and related methods and systems Pending 20-Jun-2021 000000000 0
EP-4359024-A1 Tissue culture vessel for preparation of compressed hydrogel skin grafts and related methods and systems Pending 20-Jun-2021 000000000
AU-2021391840-A1 Device and method for preparing a cell suspension Pending 01-Dec-2020 C12M45/06
To view CUTISS’s complete patent history, request access »

CUTISS Executive Team (9)

Name Title Board Seat
Daniela Marino Ph.D Co-Founder, Chief Executive Officer, Managing Director, and Board Member
Martin Meuli Co-Founder & President of the Board of Directors
Kathi Mujynya Chief Operation Officer
Fabienne Hartmann-Fritsch Co-Founder, Chief Technology Officer & Chief Clinical Officer
Vincent Ronfard Chief Innovation Officer
You’re viewing 5 of 9 executive team members. Get the full list »

CUTISS Board Members (5)

Name Representing Role Since
Daniela Marino Ph.D CUTISS Co-Founder, Chief Executive Officer, Managing Director, and Board Member 000 0000
Ernst Reichmann Ph.D CUTISS Co-Founder & Board Member 000 0000
Gerard Ber Ph.D Self Board Member 000 0000
Giammaria Giuliani Giuliani Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

CUTISS Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CUTISS Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cherry Bay Capital Group Family Office Minority 000 0000 000000 0
Lichtsteiner Foundation Limited Partner Minority 000 0000 000000 0
GG 1978 Venture Capital Minority 000 0000 000000 0
Government of France Government 000 0000 000000 0
GISEV Family Office Family Office Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial

CUTISS FAQs

  • When was CUTISS founded?

    CUTISS was founded in 2015.

  • Who is the founder of CUTISS?

    Daniela Marino Ph.D, Martin Meuli, Fabienne Hartmann-Fritsch, Clemens Schiestl MD, and Ernst Reichmann Ph.D are the founders of CUTISS.

  • Who is the CEO of CUTISS?

    Daniela Marino Ph.D is the CEO of CUTISS.

  • Where is CUTISS headquartered?

    CUTISS is headquartered in Schlieren, Switzerland.

  • What is the size of CUTISS?

    CUTISS has 50 total employees.

  • What industry is CUTISS in?

    CUTISS’s primary industry is Biotechnology.

  • Is CUTISS a private or public company?

    CUTISS is a Private company.

  • What is the current valuation of CUTISS?

    The current valuation of CUTISS is 00000.

  • What is CUTISS’s current revenue?

    The current revenue for CUTISS is 00000.

  • How much funding has CUTISS raised over time?

    CUTISS has raised $97.6M.

  • Who are CUTISS’s investors?

    Cherry Bay Capital Group, Lichtsteiner Foundation, GG 1978, Government of France, and GISEV Family Office are 5 of 14 investors who have invested in CUTISS.

  • Who are CUTISS’s competitors?

    Vericel and Mallinckrodt are competitors of CUTISS.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »